TOI ONCOLOGY INSTITUTE INC (THE)

The Oncology Institute Becomes Certified as a Patient Safety Organization

The Oncology Institute Becomes Certified as a Patient Safety Organization

Publicly traded leader in value-based oncology care raises standards in patient safety

CERRITOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced today an important step in maximizing patient safety by becoming an Agency for Healthcare Research and Quality accredited Patient Safety Organization (PSO). The TOI PSO is a newly formed component entity whose purpose is to maintain the highest standards in patients’ safety and quality by analyzing patient safety data to provide feedback, guidance, and training of TOI clinicians.

"At TOI, the quality of our patient care is our highest priority. We believe this certification will further demonstrate to our patients that we offer them the highest quality care,” said Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute. "For our health professionals, this means we are creating a culture of safety at our organization where our teammates feel empowered to report incidences and provide input to continue to elevate patient quality and care.”

Currently, due to the strict guidelines to achieve this status, there are only 100 PSOs in the United States. To receive certification as a PSO, TOI had to demonstrate compliance with AHRQ regulations, develop policies and procedures, build infrastructure for patient safety incidence reporting and data analytic methods that allow TOI to provide constructive feedback to providers. TOI PSO was granted a three-year PSO listing effective August 25, 2022, which will benefit the company’s healthcare providers and clinics.

About The Oncology Institute, Inc.

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit

Contacts

Media

The Oncology Institute

Julie Korinke

(562) 735-3226 x 88806

Juan Lezama

(562) 374-8434

Investors

Solebury Trout

Maria Lycouris



EN
12/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ONCOLOGY INSTITUTE INC (THE)

 PRESS RELEASE

The Oncology Institute Reports First Quarter 2025 Financial Results an...

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in th...

 PRESS RELEASE

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Off...

The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Direct...

 PRESS RELEASE

The Oncology Institute to Participate at the B. Riley Securities 25th ...

The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering...

 PRESS RELEASE

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on H...

The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting ...

 PRESS RELEASE

The Oncology Institute Announces First Quarter 2025 Earnings Release D...

The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers,...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch